Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now focus on its PRMT5 program and plans to update on TNG908 and TNG462 later this year.
NIO shares plummet over 8%. The company's founder eyes European expansion amid concerns over potential EU tariffs on Chinese EVs, impacting broader market sentiment.
V.F. Corp released fiscal fourth-quarter earnings results on Wednesday after the market close. The North Face and Vans owner reported a loss of 32 cents per share, missing analyst estimates for earnings of 1 cent. The company also reported $2.4 billion in sales for the quarter, missing analyst estimates of $2.41 billion.
GoodRx has been upgraded by RBC Capital Markets due to the growth potential from the Integrated Savings Program, direct contracting initiatives, and manufacturing solutions expansion.